NDTDI

NDTDI is a tricyclic tryptamine derivative which is thought to act as a serotonin receptor agonist, though its pharmacology has not been studied in detail. It is a structurally simplified analogue of LSD and is reported to retain similar effects, though with many times lower potency. It has been sold as a designer drug since 2016 and was first identified by a forensic laboratory in Slovenia in 2017.

NDTDI

Legal status
Legal status	Illegal in Latvia
Identifiers
IUPAC name N,N-diethyl-3-(methyl(1,3,4,5-tetrahydrobenzo[cd]indol-4-yl)amino)propanamide
PubChem CID	163192742
CompTox Dashboard (EPA)	DTXSID601342245
Chemical and physical data
Formula	C19H27N3O
Molar mass	313.445 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(CC)C(=O)CCN(C)C1Cc3cccc2ncc(C1)c23
InChI InChI=1S/C19H27N3O/c1-4-22(5-2)18(23)9-10-21(3)16-11-14-7-6-8-17-19(14)15(12-16)13-20-17/h6-8,13,16,20H,4-5,9-12H2,1-3H3 Key:JECGWOMOCPQHDH-UHFFFAOYSA-N

Legality

NDTDI was made illegal in Latvia in March 2017.

See also

• 4,5-DHP-DMT
• Bay R 1531
• RU-28306
• RU-24,969